nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—FGFR2—stomach cancer	0.383	1	CbGaD
Regorafenib—UGT1A9—Irinotecan—stomach cancer	0.0453	0.167	CbGbCtD
Regorafenib—UGT1A1—Irinotecan—stomach cancer	0.037	0.137	CbGbCtD
Regorafenib—ABCB1—Mitomycin—stomach cancer	0.0286	0.106	CbGbCtD
Regorafenib—ABCG2—Irinotecan—stomach cancer	0.0204	0.0753	CbGbCtD
Regorafenib—ABCG2—Fluorouracil—stomach cancer	0.0196	0.0723	CbGbCtD
Regorafenib—ABCG2—Docetaxel—stomach cancer	0.0149	0.0552	CbGbCtD
Regorafenib—CYP2B6—Irinotecan—stomach cancer	0.0143	0.053	CbGbCtD
Regorafenib—CYP2C9—Capecitabine—stomach cancer	0.0123	0.0453	CbGbCtD
Regorafenib—ABCG2—Doxorubicin—stomach cancer	0.0111	0.0411	CbGbCtD
Regorafenib—ABCG2—Methotrexate—stomach cancer	0.0108	0.0399	CbGbCtD
Regorafenib—CYP2C8—Fluorouracil—stomach cancer	0.0104	0.0385	CbGbCtD
Regorafenib—CYP2B6—Doxorubicin—stomach cancer	0.00783	0.0289	CbGbCtD
Regorafenib—ABCB1—Irinotecan—stomach cancer	0.00735	0.0272	CbGbCtD
Regorafenib—CYP2C9—Fluorouracil—stomach cancer	0.00727	0.0269	CbGbCtD
Regorafenib—ABCB1—Docetaxel—stomach cancer	0.00538	0.0199	CbGbCtD
Regorafenib—KIT—myenteric nerve plexus—stomach cancer	0.00455	0.0553	CbGeAlD
Regorafenib—CYP3A4—Irinotecan—stomach cancer	0.0044	0.0163	CbGbCtD
Regorafenib—ABCB1—Doxorubicin—stomach cancer	0.00401	0.0148	CbGbCtD
Regorafenib—ABCB1—Methotrexate—stomach cancer	0.00389	0.0144	CbGbCtD
Regorafenib—CYP3A4—Docetaxel—stomach cancer	0.00323	0.0119	CbGbCtD
Regorafenib—CYP3A4—Doxorubicin—stomach cancer	0.00241	0.00889	CbGbCtD
Regorafenib—RAF1—Topotecan—Irinotecan—stomach cancer	0.00167	0.505	CbGdCrCtD
Regorafenib—FLT4—blood vessel—stomach cancer	0.0016	0.0194	CbGeAlD
Regorafenib—FRK—hematopoietic system—stomach cancer	0.00156	0.0189	CbGeAlD
Regorafenib—DDR2—hematopoietic system—stomach cancer	0.0014	0.017	CbGeAlD
Regorafenib—EPHA2—blood vessel—stomach cancer	0.00132	0.016	CbGeAlD
Regorafenib—TEK—blood vessel—stomach cancer	0.00128	0.0156	CbGeAlD
Regorafenib—FLT1—blood vessel—stomach cancer	0.00124	0.0151	CbGeAlD
Regorafenib—DDR2—smooth muscle tissue—stomach cancer	0.00123	0.0149	CbGeAlD
Regorafenib—FRK—lymphoid tissue—stomach cancer	0.0011	0.0133	CbGeAlD
Regorafenib—PDGFRA—gall bladder—stomach cancer	0.00109	0.0133	CbGeAlD
Regorafenib—KDR—blood vessel—stomach cancer	0.00105	0.0128	CbGeAlD
Regorafenib—DDR2—lymphoid tissue—stomach cancer	0.000982	0.0119	CbGeAlD
Regorafenib—DDR2—digestive system—stomach cancer	0.00097	0.0118	CbGeAlD
Regorafenib—KIT—blood vessel—stomach cancer	0.00093	0.0113	CbGeAlD
Regorafenib—PDGFRB—blood vessel—stomach cancer	0.000908	0.011	CbGeAlD
Regorafenib—FRK—endocrine gland—stomach cancer	0.000894	0.0109	CbGeAlD
Regorafenib—KIT—gall bladder—stomach cancer	0.000875	0.0106	CbGeAlD
Regorafenib—PDGFRB—gall bladder—stomach cancer	0.000855	0.0104	CbGeAlD
Regorafenib—FLT4—hematopoietic system—stomach cancer	0.00085	0.0103	CbGeAlD
Regorafenib—FRK—liver—stomach cancer	0.000806	0.0098	CbGeAlD
Regorafenib—DDR2—endocrine gland—stomach cancer	0.000802	0.00975	CbGeAlD
Regorafenib—FLT4—epithelium—stomach cancer	0.000777	0.00945	CbGeAlD
Regorafenib—RET—hematopoietic system—stomach cancer	0.00075	0.00912	CbGeAlD
Regorafenib—DDR2—liver—stomach cancer	0.000723	0.00879	CbGeAlD
Regorafenib—FGFR2—hematopoietic system—stomach cancer	0.000713	0.00867	CbGeAlD
Regorafenib—EPHA2—hematopoietic system—stomach cancer	0.000701	0.00852	CbGeAlD
Regorafenib—ABL1—Topotecan—Irinotecan—stomach cancer	0.000693	0.21	CbGdCrCtD
Regorafenib—RET—epithelium—stomach cancer	0.000686	0.00834	CbGeAlD
Regorafenib—TEK—hematopoietic system—stomach cancer	0.000684	0.00831	CbGeAlD
Regorafenib—FLT1—hematopoietic system—stomach cancer	0.000661	0.00804	CbGeAlD
Regorafenib—RAF1—hematopoietic system—stomach cancer	0.000657	0.00799	CbGeAlD
Regorafenib—FGFR2—epithelium—stomach cancer	0.000652	0.00792	CbGeAlD
Regorafenib—EPHA2—epithelium—stomach cancer	0.000641	0.00779	CbGeAlD
Regorafenib—BRAF—bone marrow—stomach cancer	0.000632	0.00769	CbGeAlD
Regorafenib—FGFR2—smooth muscle tissue—stomach cancer	0.000628	0.00764	CbGeAlD
Regorafenib—TEK—epithelium—stomach cancer	0.000625	0.0076	CbGeAlD
Regorafenib—PDGFRA—hematopoietic system—stomach cancer	0.000619	0.00753	CbGeAlD
Regorafenib—FLT1—epithelium—stomach cancer	0.000604	0.00735	CbGeAlD
Regorafenib—TEK—smooth muscle tissue—stomach cancer	0.000602	0.00732	CbGeAlD
Regorafenib—RAF1—epithelium—stomach cancer	0.000601	0.0073	CbGeAlD
Regorafenib—UGT1A9—digestive system—stomach cancer	0.0006	0.00729	CbGeAlD
Regorafenib—FLT4—lymphoid tissue—stomach cancer	0.000598	0.00728	CbGeAlD
Regorafenib—UGT1A1—hematopoietic system—stomach cancer	0.000591	0.00718	CbGeAlD
Regorafenib—FLT1—smooth muscle tissue—stomach cancer	0.000582	0.00708	CbGeAlD
Regorafenib—RAF1—smooth muscle tissue—stomach cancer	0.000579	0.00704	CbGeAlD
Regorafenib—EPHA2—pancreas—stomach cancer	0.000571	0.00694	CbGeAlD
Regorafenib—KDR—hematopoietic system—stomach cancer	0.000559	0.00679	CbGeAlD
Regorafenib—TEK—pancreas—stomach cancer	0.000557	0.00677	CbGeAlD
Regorafenib—DDR2—lymph node—stomach cancer	0.000554	0.00674	CbGeAlD
Regorafenib—PDGFRA—smooth muscle tissue—stomach cancer	0.000546	0.00663	CbGeAlD
Regorafenib—FLT4—bone marrow—stomach cancer	0.000545	0.00662	CbGeAlD
Regorafenib—FLT1—pancreas—stomach cancer	0.000538	0.00654	CbGeAlD
Regorafenib—RAF1—pancreas—stomach cancer	0.000535	0.0065	CbGeAlD
Regorafenib—RET—lymphoid tissue—stomach cancer	0.000528	0.00642	CbGeAlD
Regorafenib—MAPK11—lymph node—stomach cancer	0.000525	0.00639	CbGeAlD
Regorafenib—RET—digestive system—stomach cancer	0.000522	0.00634	CbGeAlD
Regorafenib—BRAF—liver—stomach cancer	0.000511	0.00621	CbGeAlD
Regorafenib—KDR—epithelium—stomach cancer	0.000511	0.00621	CbGeAlD
Regorafenib—FGFR2—digestive system—stomach cancer	0.000496	0.00603	CbGeAlD
Regorafenib—UGT1A9—endocrine gland—stomach cancer	0.000495	0.00602	CbGeAlD
Regorafenib—KIT—hematopoietic system—stomach cancer	0.000495	0.00602	CbGeAlD
Regorafenib—EPHA2—lymphoid tissue—stomach cancer	0.000493	0.006	CbGeAlD
Regorafenib—KDR—smooth muscle tissue—stomach cancer	0.000492	0.00598	CbGeAlD
Regorafenib—FLT4—endocrine gland—stomach cancer	0.000488	0.00594	CbGeAlD
Regorafenib—EPHX2—liver—stomach cancer	0.000488	0.00594	CbGeAlD
Regorafenib—EPHA2—digestive system—stomach cancer	0.000487	0.00592	CbGeAlD
Regorafenib—PDGFRB—hematopoietic system—stomach cancer	0.000484	0.00588	CbGeAlD
Regorafenib—TEK—lymphoid tissue—stomach cancer	0.000481	0.00585	CbGeAlD
Regorafenib—FLT1—lymphoid tissue—stomach cancer	0.000465	0.00566	CbGeAlD
Regorafenib—RAF1—lymphoid tissue—stomach cancer	0.000463	0.00562	CbGeAlD
Regorafenib—FLT1—digestive system—stomach cancer	0.00046	0.00559	CbGeAlD
Regorafenib—RAF1—digestive system—stomach cancer	0.000457	0.00556	CbGeAlD
Regorafenib—KIT—epithelium—stomach cancer	0.000453	0.0055	CbGeAlD
Regorafenib—UGT1A9—liver—stomach cancer	0.000447	0.00543	CbGeAlD
Regorafenib—PDGFRB—epithelium—stomach cancer	0.000442	0.00537	CbGeAlD
Regorafenib—FLT4—liver—stomach cancer	0.00044	0.00535	CbGeAlD
Regorafenib—KIT—smooth muscle tissue—stomach cancer	0.000436	0.0053	CbGeAlD
Regorafenib—PDGFRA—lymphoid tissue—stomach cancer	0.000436	0.0053	CbGeAlD
Regorafenib—FGFR1—liver—stomach cancer	0.000434	0.00528	CbGeAlD
Regorafenib—RET—endocrine gland—stomach cancer	0.000431	0.00524	CbGeAlD
Regorafenib—ABL1—hematopoietic system—stomach cancer	0.000431	0.00524	CbGeAlD
Regorafenib—PDGFRA—digestive system—stomach cancer	0.000431	0.00524	CbGeAlD
Regorafenib—PDGFRB—smooth muscle tissue—stomach cancer	0.000426	0.00518	CbGeAlD
Regorafenib—RAF1—bone marrow—stomach cancer	0.000421	0.00512	CbGeAlD
Regorafenib—UGT1A1—digestive system—stomach cancer	0.000411	0.005	CbGeAlD
Regorafenib—FGFR2—endocrine gland—stomach cancer	0.00041	0.00498	CbGeAlD
Regorafenib—KIT—pancreas—stomach cancer	0.000403	0.0049	CbGeAlD
Regorafenib—EPHA2—endocrine gland—stomach cancer	0.000403	0.0049	CbGeAlD
Regorafenib—PDGFRB—pancreas—stomach cancer	0.000394	0.00479	CbGeAlD
Regorafenib—KDR—lymphoid tissue—stomach cancer	0.000393	0.00478	CbGeAlD
Regorafenib—TEK—endocrine gland—stomach cancer	0.000393	0.00478	CbGeAlD
Regorafenib—BRAF—lymph node—stomach cancer	0.000392	0.00476	CbGeAlD
Regorafenib—KDR—digestive system—stomach cancer	0.000389	0.00472	CbGeAlD
Regorafenib—FLT1—endocrine gland—stomach cancer	0.00038	0.00462	CbGeAlD
Regorafenib—ABL1—smooth muscle tissue—stomach cancer	0.00038	0.00462	CbGeAlD
Regorafenib—RAF1—endocrine gland—stomach cancer	0.000378	0.00459	CbGeAlD
Regorafenib—EPHX2—lymph node—stomach cancer	0.000374	0.00455	CbGeAlD
Regorafenib—FGFR2—liver—stomach cancer	0.000369	0.00449	CbGeAlD
Regorafenib—EPHA2—liver—stomach cancer	0.000363	0.00441	CbGeAlD
Regorafenib—KDR—bone marrow—stomach cancer	0.000358	0.00435	CbGeAlD
Regorafenib—PDGFRA—endocrine gland—stomach cancer	0.000356	0.00433	CbGeAlD
Regorafenib—TEK—liver—stomach cancer	0.000354	0.00431	CbGeAlD
Regorafenib—ABL1—pancreas—stomach cancer	0.000351	0.00427	CbGeAlD
Regorafenib—KIT—lymphoid tissue—stomach cancer	0.000349	0.00424	CbGeAlD
Regorafenib—KIT—digestive system—stomach cancer	0.000344	0.00419	CbGeAlD
Regorafenib—FLT1—liver—stomach cancer	0.000342	0.00416	CbGeAlD
Regorafenib—PDGFRB—lymphoid tissue—stomach cancer	0.00034	0.00414	CbGeAlD
Regorafenib—RAF1—liver—stomach cancer	0.00034	0.00414	CbGeAlD
Regorafenib—UGT1A1—endocrine gland—stomach cancer	0.00034	0.00413	CbGeAlD
Regorafenib—FLT4—lymph node—stomach cancer	0.000338	0.00411	CbGeAlD
Regorafenib—PDGFRB—digestive system—stomach cancer	0.000336	0.00409	CbGeAlD
Regorafenib—FGFR1—lymph node—stomach cancer	0.000333	0.00405	CbGeAlD
Regorafenib—KDR—endocrine gland—stomach cancer	0.000321	0.0039	CbGeAlD
Regorafenib—PDGFRA—liver—stomach cancer	0.000321	0.0039	CbGeAlD
Regorafenib—CYP2C19—hematopoietic system—stomach cancer	0.00032	0.00389	CbGeAlD
Regorafenib—KIT—bone marrow—stomach cancer	0.000317	0.00386	CbGeAlD
Regorafenib—PDGFRB—bone marrow—stomach cancer	0.00031	0.00377	CbGeAlD
Regorafenib—UGT1A1—liver—stomach cancer	0.000306	0.00372	CbGeAlD
Regorafenib—ABL1—lymphoid tissue—stomach cancer	0.000303	0.00369	CbGeAlD
Regorafenib—ABL1—digestive system—stomach cancer	0.0003	0.00364	CbGeAlD
Regorafenib—RET—lymph node—stomach cancer	0.000298	0.00362	CbGeAlD
Regorafenib—KDR—liver—stomach cancer	0.000289	0.00352	CbGeAlD
Regorafenib—KIT—endocrine gland—stomach cancer	0.000285	0.00346	CbGeAlD
Regorafenib—CYP2C8—hematopoietic system—stomach cancer	0.00028	0.0034	CbGeAlD
Regorafenib—EPHA2—lymph node—stomach cancer	0.000278	0.00338	CbGeAlD
Regorafenib—PDGFRB—endocrine gland—stomach cancer	0.000278	0.00338	CbGeAlD
Regorafenib—ABL1—bone marrow—stomach cancer	0.000276	0.00336	CbGeAlD
Regorafenib—TEK—lymph node—stomach cancer	0.000272	0.0033	CbGeAlD
Regorafenib—FLT1—lymph node—stomach cancer	0.000263	0.00319	CbGeAlD
Regorafenib—RAF1—lymph node—stomach cancer	0.000261	0.00317	CbGeAlD
Regorafenib—KIT—liver—stomach cancer	0.000257	0.00312	CbGeAlD
Regorafenib—ABCB1—blood vessel—stomach cancer	0.000252	0.00306	CbGeAlD
Regorafenib—CYP2B6—hematopoietic system—stomach cancer	0.000251	0.00305	CbGeAlD
Regorafenib—PDGFRB—liver—stomach cancer	0.000251	0.00305	CbGeAlD
Regorafenib—CYP2C9—hematopoietic system—stomach cancer	0.000248	0.00302	CbGeAlD
Regorafenib—ABL1—endocrine gland—stomach cancer	0.000248	0.00301	CbGeAlD
Regorafenib—PDGFRA—lymph node—stomach cancer	0.000246	0.00299	CbGeAlD
Regorafenib—ABL1—liver—stomach cancer	0.000223	0.00271	CbGeAlD
Regorafenib—CYP2C19—digestive system—stomach cancer	0.000223	0.00271	CbGeAlD
Regorafenib—KDR—lymph node—stomach cancer	0.000222	0.0027	CbGeAlD
Regorafenib—KIT—lymph node—stomach cancer	0.000197	0.00239	CbGeAlD
Regorafenib—PDGFRB—lymph node—stomach cancer	0.000192	0.00234	CbGeAlD
Regorafenib—CYP3A4—hematopoietic system—stomach cancer	0.000189	0.0023	CbGeAlD
Regorafenib—Neoplasm—Doxorubicin—stomach cancer	0.000187	0.00197	CcSEcCtD
Regorafenib—Anaemia—Fluorouracil—stomach cancer	0.000185	0.00196	CcSEcCtD
Regorafenib—Infestation—Docetaxel—stomach cancer	0.000185	0.00195	CcSEcCtD
Regorafenib—Infestation NOS—Docetaxel—stomach cancer	0.000185	0.00195	CcSEcCtD
Regorafenib—CYP2C19—endocrine gland—stomach cancer	0.000184	0.00224	CbGeAlD
Regorafenib—Stevens-Johnson syndrome—Docetaxel—stomach cancer	0.000183	0.00194	CcSEcCtD
Regorafenib—Acute coronary syndrome—Docetaxel—stomach cancer	0.000182	0.00193	CcSEcCtD
Regorafenib—Weight decreased—Capecitabine—stomach cancer	0.000182	0.00192	CcSEcCtD
Regorafenib—Myocardial infarction—Docetaxel—stomach cancer	0.000181	0.00192	CcSEcCtD
Regorafenib—Hypertension—Irinotecan—stomach cancer	0.000181	0.00191	CcSEcCtD
Regorafenib—Stomatitis—Docetaxel—stomach cancer	0.00018	0.00191	CcSEcCtD
Regorafenib—Leukopenia—Fluorouracil—stomach cancer	0.000179	0.00189	CcSEcCtD
Regorafenib—Infestation—Capecitabine—stomach cancer	0.000179	0.00189	CcSEcCtD
Regorafenib—Infestation NOS—Capecitabine—stomach cancer	0.000179	0.00189	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Capecitabine—stomach cancer	0.000178	0.00188	CcSEcCtD
Regorafenib—Acute coronary syndrome—Capecitabine—stomach cancer	0.000177	0.00187	CcSEcCtD
Regorafenib—CYP2B6—lymphoid tissue—stomach cancer	0.000177	0.00215	CbGeAlD
Regorafenib—Myocardial infarction—Capecitabine—stomach cancer	0.000176	0.00186	CcSEcCtD
Regorafenib—Hepatobiliary disease—Docetaxel—stomach cancer	0.000175	0.00185	CcSEcCtD
Regorafenib—Stomatitis—Capecitabine—stomach cancer	0.000175	0.00184	CcSEcCtD
Regorafenib—CYP2B6—digestive system—stomach cancer	0.000174	0.00212	CbGeAlD
Regorafenib—ABCG2—bone marrow—stomach cancer	0.000174	0.00212	CbGeAlD
Regorafenib—CYP2C9—digestive system—stomach cancer	0.000173	0.0021	CbGeAlD
Regorafenib—ABL1—lymph node—stomach cancer	0.000171	0.00208	CbGeAlD
Regorafenib—Infection—Irinotecan—stomach cancer	0.00017	0.00179	CcSEcCtD
Regorafenib—Hepatobiliary disease—Capecitabine—stomach cancer	0.000169	0.00179	CcSEcCtD
Regorafenib—Nervous system disorder—Irinotecan—stomach cancer	0.000167	0.00177	CcSEcCtD
Regorafenib—Thrombocytopenia—Irinotecan—stomach cancer	0.000167	0.00177	CcSEcCtD
Regorafenib—Haemoglobin—Docetaxel—stomach cancer	0.000167	0.00176	CcSEcCtD
Regorafenib—Haemorrhage—Docetaxel—stomach cancer	0.000166	0.00175	CcSEcCtD
Regorafenib—CYP2C19—liver—stomach cancer	0.000166	0.00202	CbGeAlD
Regorafenib—Urinary tract disorder—Docetaxel—stomach cancer	0.000164	0.00173	CcSEcCtD
Regorafenib—Connective tissue disorder—Docetaxel—stomach cancer	0.000163	0.00172	CcSEcCtD
Regorafenib—ABL1—Daunorubicin—Epirubicin—stomach cancer	0.000163	0.0493	CbGdCrCtD
Regorafenib—ABL1—Idarubicin—Epirubicin—stomach cancer	0.000163	0.0493	CbGdCrCtD
Regorafenib—ABL1—Doxorubicin—Epirubicin—stomach cancer	0.000163	0.0493	CbGdCrCtD
Regorafenib—Urethral disorder—Docetaxel—stomach cancer	0.000163	0.00172	CcSEcCtD
Regorafenib—Hyponatraemia—Epirubicin—stomach cancer	0.000163	0.00172	CcSEcCtD
Regorafenib—Infection—Fluorouracil—stomach cancer	0.000162	0.00172	CcSEcCtD
Regorafenib—Haemoglobin—Capecitabine—stomach cancer	0.000162	0.00171	CcSEcCtD
Regorafenib—Haemorrhage—Capecitabine—stomach cancer	0.000161	0.0017	CcSEcCtD
Regorafenib—CYP2C8—endocrine gland—stomach cancer	0.000161	0.00195	CbGeAlD
Regorafenib—Nervous system disorder—Fluorouracil—stomach cancer	0.00016	0.00169	CcSEcCtD
Regorafenib—Thrombocytopenia—Fluorouracil—stomach cancer	0.00016	0.00169	CcSEcCtD
Regorafenib—Urinary tract disorder—Capecitabine—stomach cancer	0.000159	0.00168	CcSEcCtD
Regorafenib—Connective tissue disorder—Capecitabine—stomach cancer	0.000158	0.00167	CcSEcCtD
Regorafenib—Urethral disorder—Capecitabine—stomach cancer	0.000158	0.00167	CcSEcCtD
Regorafenib—Erythema multiforme—Docetaxel—stomach cancer	0.000157	0.00166	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Methotrexate—stomach cancer	0.000156	0.00165	CcSEcCtD
Regorafenib—Cardiac disorder—Docetaxel—stomach cancer	0.000154	0.00163	CcSEcCtD
Regorafenib—Erythema multiforme—Capecitabine—stomach cancer	0.000152	0.00161	CcSEcCtD
Regorafenib—ABL1—Daunorubicin—Doxorubicin—stomach cancer	0.000151	0.0456	CbGdCrCtD
Regorafenib—ABL1—Epirubicin—Doxorubicin—stomach cancer	0.000151	0.0456	CbGdCrCtD
Regorafenib—ABL1—Idarubicin—Doxorubicin—stomach cancer	0.000151	0.0456	CbGdCrCtD
Regorafenib—Angiopathy—Docetaxel—stomach cancer	0.000151	0.00159	CcSEcCtD
Regorafenib—Hyponatraemia—Doxorubicin—stomach cancer	0.00015	0.00159	CcSEcCtD
Regorafenib—Mediastinal disorder—Docetaxel—stomach cancer	0.00015	0.00158	CcSEcCtD
Regorafenib—Cardiac disorder—Capecitabine—stomach cancer	0.000149	0.00158	CcSEcCtD
Regorafenib—Dry skin—Epirubicin—stomach cancer	0.000148	0.00157	CcSEcCtD
Regorafenib—Decreased appetite—Irinotecan—stomach cancer	0.000148	0.00157	CcSEcCtD
Regorafenib—Hypokalaemia—Epirubicin—stomach cancer	0.000147	0.00156	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Irinotecan—stomach cancer	0.000147	0.00156	CcSEcCtD
Regorafenib—Fatigue—Irinotecan—stomach cancer	0.000147	0.00155	CcSEcCtD
Regorafenib—Alopecia—Docetaxel—stomach cancer	0.000147	0.00155	CcSEcCtD
Regorafenib—Pain—Irinotecan—stomach cancer	0.000146	0.00154	CcSEcCtD
Regorafenib—Angiopathy—Capecitabine—stomach cancer	0.000146	0.00154	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Epirubicin—stomach cancer	0.000146	0.00154	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Epirubicin—stomach cancer	0.000146	0.00154	CcSEcCtD
Regorafenib—Mediastinal disorder—Capecitabine—stomach cancer	0.000145	0.00153	CcSEcCtD
Regorafenib—CYP2C8—liver—stomach cancer	0.000145	0.00176	CbGeAlD
Regorafenib—Malnutrition—Docetaxel—stomach cancer	0.000145	0.00153	CcSEcCtD
Regorafenib—CYP2B6—endocrine gland—stomach cancer	0.000144	0.00175	CbGeAlD
Regorafenib—Alanine aminotransferase increased—Epirubicin—stomach cancer	0.000143	0.00151	CcSEcCtD
Regorafenib—CYP2C9—endocrine gland—stomach cancer	0.000143	0.00173	CbGeAlD
Regorafenib—Decreased appetite—Fluorouracil—stomach cancer	0.000142	0.0015	CcSEcCtD
Regorafenib—Alopecia—Capecitabine—stomach cancer	0.000142	0.0015	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Fluorouracil—stomach cancer	0.000141	0.00149	CcSEcCtD
Regorafenib—ABCG2—liver—stomach cancer	0.000141	0.00171	CbGeAlD
Regorafenib—Malnutrition—Capecitabine—stomach cancer	0.00014	0.00148	CcSEcCtD
Regorafenib—Neutropenia—Methotrexate—stomach cancer	0.00014	0.00148	CcSEcCtD
Regorafenib—Pain—Fluorouracil—stomach cancer	0.00014	0.00148	CcSEcCtD
Regorafenib—Gastrointestinal pain—Irinotecan—stomach cancer	0.00014	0.00147	CcSEcCtD
Regorafenib—Dry skin—Doxorubicin—stomach cancer	0.000137	0.00145	CcSEcCtD
Regorafenib—Hypokalaemia—Doxorubicin—stomach cancer	0.000136	0.00144	CcSEcCtD
Regorafenib—Body temperature increased—Irinotecan—stomach cancer	0.000135	0.00143	CcSEcCtD
Regorafenib—Abdominal pain—Irinotecan—stomach cancer	0.000135	0.00143	CcSEcCtD
Regorafenib—Aspartate aminotransferase increased—Doxorubicin—stomach cancer	0.000135	0.00143	CcSEcCtD
Regorafenib—Toxic epidermal necrolysis—Doxorubicin—stomach cancer	0.000135	0.00143	CcSEcCtD
Regorafenib—ABCB1—hematopoietic system—stomach cancer	0.000134	0.00163	CbGeAlD
Regorafenib—Anaemia—Docetaxel—stomach cancer	0.000134	0.00141	CcSEcCtD
Regorafenib—Infestation NOS—Methotrexate—stomach cancer	0.000133	0.00141	CcSEcCtD
Regorafenib—Infestation—Methotrexate—stomach cancer	0.000133	0.00141	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Methotrexate—stomach cancer	0.000132	0.0014	CcSEcCtD
Regorafenib—Alanine aminotransferase increased—Doxorubicin—stomach cancer	0.000132	0.0014	CcSEcCtD
Regorafenib—CYP3A4—digestive system—stomach cancer	0.000132	0.0016	CbGeAlD
Regorafenib—Tremor—Capecitabine—stomach cancer	0.000131	0.00139	CcSEcCtD
Regorafenib—Neutropenia—Epirubicin—stomach cancer	0.000131	0.00138	CcSEcCtD
Regorafenib—Stomatitis—Methotrexate—stomach cancer	0.00013	0.00137	CcSEcCtD
Regorafenib—CYP2B6—liver—stomach cancer	0.00013	0.00158	CbGeAlD
Regorafenib—Leukopenia—Docetaxel—stomach cancer	0.000129	0.00137	CcSEcCtD
Regorafenib—Anaemia—Capecitabine—stomach cancer	0.000129	0.00137	CcSEcCtD
Regorafenib—Body temperature increased—Fluorouracil—stomach cancer	0.000129	0.00137	CcSEcCtD
Regorafenib—CYP2C9—liver—stomach cancer	0.000129	0.00156	CbGeAlD
Regorafenib—Weight decreased—Epirubicin—stomach cancer	0.000127	0.00134	CcSEcCtD
Regorafenib—Hepatobiliary disease—Methotrexate—stomach cancer	0.000126	0.00133	CcSEcCtD
Regorafenib—Leukopenia—Capecitabine—stomach cancer	0.000125	0.00132	CcSEcCtD
Regorafenib—Hypertension—Docetaxel—stomach cancer	0.000125	0.00132	CcSEcCtD
Regorafenib—Infestation—Epirubicin—stomach cancer	0.000125	0.00132	CcSEcCtD
Regorafenib—Infestation NOS—Epirubicin—stomach cancer	0.000125	0.00132	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Epirubicin—stomach cancer	0.000124	0.00131	CcSEcCtD
Regorafenib—ABCB1—epithelium—stomach cancer	0.000123	0.00149	CbGeAlD
Regorafenib—Asthenia—Irinotecan—stomach cancer	0.000122	0.00129	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—stomach cancer	0.000122	0.00129	CcSEcCtD
Regorafenib—Stomatitis—Epirubicin—stomach cancer	0.000122	0.00129	CcSEcCtD
Regorafenib—Neutropenia—Doxorubicin—stomach cancer	0.000121	0.00128	CcSEcCtD
Regorafenib—Hypertension—Capecitabine—stomach cancer	0.000121	0.00128	CcSEcCtD
Regorafenib—Dry mouth—Docetaxel—stomach cancer	0.00012	0.00127	CcSEcCtD
Regorafenib—Haemoglobin—Methotrexate—stomach cancer	0.00012	0.00127	CcSEcCtD
Regorafenib—Haemorrhage—Methotrexate—stomach cancer	0.00012	0.00126	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—stomach cancer	0.000118	0.00125	CcSEcCtD
Regorafenib—Urinary tract disorder—Methotrexate—stomach cancer	0.000118	0.00125	CcSEcCtD
Regorafenib—Hepatobiliary disease—Epirubicin—stomach cancer	0.000118	0.00125	CcSEcCtD
Regorafenib—Urethral disorder—Methotrexate—stomach cancer	0.000117	0.00124	CcSEcCtD
Regorafenib—Infection—Docetaxel—stomach cancer	0.000117	0.00124	CcSEcCtD
Regorafenib—Weight decreased—Doxorubicin—stomach cancer	0.000117	0.00124	CcSEcCtD
Regorafenib—Diarrhoea—Irinotecan—stomach cancer	0.000117	0.00123	CcSEcCtD
Regorafenib—Dry mouth—Capecitabine—stomach cancer	0.000117	0.00123	CcSEcCtD
Regorafenib—Nervous system disorder—Docetaxel—stomach cancer	0.000116	0.00122	CcSEcCtD
Regorafenib—Thrombocytopenia—Docetaxel—stomach cancer	0.000116	0.00122	CcSEcCtD
Regorafenib—Infestation—Doxorubicin—stomach cancer	0.000115	0.00122	CcSEcCtD
Regorafenib—Infestation NOS—Doxorubicin—stomach cancer	0.000115	0.00122	CcSEcCtD
Regorafenib—Skin disorder—Docetaxel—stomach cancer	0.000115	0.00121	CcSEcCtD
Regorafenib—Stevens-Johnson syndrome—Doxorubicin—stomach cancer	0.000114	0.00121	CcSEcCtD
Regorafenib—Infection—Capecitabine—stomach cancer	0.000114	0.0012	CcSEcCtD
Regorafenib—Erythema multiforme—Methotrexate—stomach cancer	0.000113	0.0012	CcSEcCtD
Regorafenib—Haemoglobin—Epirubicin—stomach cancer	0.000113	0.00119	CcSEcCtD
Regorafenib—Stomatitis—Doxorubicin—stomach cancer	0.000113	0.00119	CcSEcCtD
Regorafenib—Nervous system disorder—Capecitabine—stomach cancer	0.000112	0.00118	CcSEcCtD
Regorafenib—Haemorrhage—Epirubicin—stomach cancer	0.000112	0.00118	CcSEcCtD
Regorafenib—Diarrhoea—Fluorouracil—stomach cancer	0.000112	0.00118	CcSEcCtD
Regorafenib—Thrombocytopenia—Capecitabine—stomach cancer	0.000112	0.00118	CcSEcCtD
Regorafenib—Cardiac disorder—Methotrexate—stomach cancer	0.000111	0.00117	CcSEcCtD
Regorafenib—Skin disorder—Capecitabine—stomach cancer	0.000111	0.00117	CcSEcCtD
Regorafenib—Urinary tract disorder—Epirubicin—stomach cancer	0.000111	0.00117	CcSEcCtD
Regorafenib—Connective tissue disorder—Epirubicin—stomach cancer	0.00011	0.00116	CcSEcCtD
Regorafenib—Urethral disorder—Epirubicin—stomach cancer	0.00011	0.00116	CcSEcCtD
Regorafenib—Hepatobiliary disease—Doxorubicin—stomach cancer	0.000109	0.00115	CcSEcCtD
Regorafenib—ABCB1—pancreas—stomach cancer	0.000109	0.00133	CbGeAlD
Regorafenib—CYP3A4—endocrine gland—stomach cancer	0.000109	0.00132	CbGeAlD
Regorafenib—Angiopathy—Methotrexate—stomach cancer	0.000109	0.00115	CcSEcCtD
Regorafenib—Vomiting—Irinotecan—stomach cancer	0.000109	0.00115	CcSEcCtD
Regorafenib—ABCG2—lymph node—stomach cancer	0.000108	0.00131	CbGeAlD
Regorafenib—Mediastinal disorder—Methotrexate—stomach cancer	0.000108	0.00114	CcSEcCtD
Regorafenib—Rash—Irinotecan—stomach cancer	0.000108	0.00114	CcSEcCtD
Regorafenib—Dermatitis—Irinotecan—stomach cancer	0.000108	0.00114	CcSEcCtD
Regorafenib—Headache—Irinotecan—stomach cancer	0.000107	0.00113	CcSEcCtD
Regorafenib—Erythema multiforme—Epirubicin—stomach cancer	0.000106	0.00112	CcSEcCtD
Regorafenib—Alopecia—Methotrexate—stomach cancer	0.000106	0.00112	CcSEcCtD
Regorafenib—Malnutrition—Methotrexate—stomach cancer	0.000104	0.0011	CcSEcCtD
Regorafenib—Haemoglobin—Doxorubicin—stomach cancer	0.000104	0.0011	CcSEcCtD
Regorafenib—Cardiac disorder—Epirubicin—stomach cancer	0.000104	0.0011	CcSEcCtD
Regorafenib—Vomiting—Fluorouracil—stomach cancer	0.000104	0.0011	CcSEcCtD
Regorafenib—Haemorrhage—Doxorubicin—stomach cancer	0.000104	0.0011	CcSEcCtD
Regorafenib—Rash—Fluorouracil—stomach cancer	0.000103	0.00109	CcSEcCtD
Regorafenib—Dermatitis—Fluorouracil—stomach cancer	0.000103	0.00109	CcSEcCtD
Regorafenib—Decreased appetite—Docetaxel—stomach cancer	0.000103	0.00108	CcSEcCtD
Regorafenib—Headache—Fluorouracil—stomach cancer	0.000102	0.00108	CcSEcCtD
Regorafenib—Urinary tract disorder—Doxorubicin—stomach cancer	0.000102	0.00108	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Docetaxel—stomach cancer	0.000102	0.00108	CcSEcCtD
Regorafenib—Connective tissue disorder—Doxorubicin—stomach cancer	0.000102	0.00108	CcSEcCtD
Regorafenib—Fatigue—Docetaxel—stomach cancer	0.000102	0.00107	CcSEcCtD
Regorafenib—Angiopathy—Epirubicin—stomach cancer	0.000102	0.00107	CcSEcCtD
Regorafenib—Urethral disorder—Doxorubicin—stomach cancer	0.000102	0.00107	CcSEcCtD
Regorafenib—Nausea—Irinotecan—stomach cancer	0.000101	0.00107	CcSEcCtD
Regorafenib—Mediastinal disorder—Epirubicin—stomach cancer	0.000101	0.00107	CcSEcCtD
Regorafenib—Pain—Docetaxel—stomach cancer	0.000101	0.00107	CcSEcCtD
Regorafenib—Decreased appetite—Capecitabine—stomach cancer	9.93e-05	0.00105	CcSEcCtD
Regorafenib—Alopecia—Epirubicin—stomach cancer	9.9e-05	0.00105	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Capecitabine—stomach cancer	9.86e-05	0.00104	CcSEcCtD
Regorafenib—Fatigue—Capecitabine—stomach cancer	9.85e-05	0.00104	CcSEcCtD
Regorafenib—CYP3A4—liver—stomach cancer	9.81e-05	0.00119	CbGeAlD
Regorafenib—Erythema multiforme—Doxorubicin—stomach cancer	9.8e-05	0.00104	CcSEcCtD
Regorafenib—Pain—Capecitabine—stomach cancer	9.77e-05	0.00103	CcSEcCtD
Regorafenib—Malnutrition—Epirubicin—stomach cancer	9.75e-05	0.00103	CcSEcCtD
Regorafenib—Nausea—Fluorouracil—stomach cancer	9.71e-05	0.00103	CcSEcCtD
Regorafenib—Gastrointestinal pain—Docetaxel—stomach cancer	9.65e-05	0.00102	CcSEcCtD
Regorafenib—Anaemia—Methotrexate—stomach cancer	9.63e-05	0.00102	CcSEcCtD
Regorafenib—Cardiac disorder—Doxorubicin—stomach cancer	9.62e-05	0.00102	CcSEcCtD
Regorafenib—ABCB1—lymphoid tissue—stomach cancer	9.44e-05	0.00115	CbGeAlD
Regorafenib—Angiopathy—Doxorubicin—stomach cancer	9.41e-05	0.000994	CcSEcCtD
Regorafenib—Gastrointestinal pain—Capecitabine—stomach cancer	9.34e-05	0.000987	CcSEcCtD
Regorafenib—Mediastinal disorder—Doxorubicin—stomach cancer	9.34e-05	0.000987	CcSEcCtD
Regorafenib—Abdominal pain—Docetaxel—stomach cancer	9.33e-05	0.000986	CcSEcCtD
Regorafenib—Body temperature increased—Docetaxel—stomach cancer	9.33e-05	0.000986	CcSEcCtD
Regorafenib—Leukopenia—Methotrexate—stomach cancer	9.33e-05	0.000986	CcSEcCtD
Regorafenib—ABCB1—digestive system—stomach cancer	9.32e-05	0.00113	CbGeAlD
Regorafenib—Alopecia—Doxorubicin—stomach cancer	9.16e-05	0.000968	CcSEcCtD
Regorafenib—Abdominal pain—Capecitabine—stomach cancer	9.03e-05	0.000954	CcSEcCtD
Regorafenib—Body temperature increased—Capecitabine—stomach cancer	9.03e-05	0.000954	CcSEcCtD
Regorafenib—Malnutrition—Doxorubicin—stomach cancer	9.02e-05	0.000953	CcSEcCtD
Regorafenib—Anaemia—Epirubicin—stomach cancer	9.01e-05	0.000952	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	8.81e-05	0.000931	CcSEcCtD
Regorafenib—Leukopenia—Epirubicin—stomach cancer	8.73e-05	0.000922	CcSEcCtD
Regorafenib—ABCB1—bone marrow—stomach cancer	8.59e-05	0.00104	CbGeAlD
Regorafenib—Asthenia—Docetaxel—stomach cancer	8.47e-05	0.000895	CcSEcCtD
Regorafenib—Infection—Methotrexate—stomach cancer	8.45e-05	0.000893	CcSEcCtD
Regorafenib—Hypertension—Epirubicin—stomach cancer	8.42e-05	0.00089	CcSEcCtD
Regorafenib—Nervous system disorder—Methotrexate—stomach cancer	8.34e-05	0.000881	CcSEcCtD
Regorafenib—Anaemia—Doxorubicin—stomach cancer	8.34e-05	0.000881	CcSEcCtD
Regorafenib—Thrombocytopenia—Methotrexate—stomach cancer	8.33e-05	0.00088	CcSEcCtD
Regorafenib—Skin disorder—Methotrexate—stomach cancer	8.26e-05	0.000873	CcSEcCtD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	8.25e-05	0.000871	CcSEcCtD
Regorafenib—Asthenia—Capecitabine—stomach cancer	8.2e-05	0.000866	CcSEcCtD
Regorafenib—Dry mouth—Epirubicin—stomach cancer	8.12e-05	0.000858	CcSEcCtD
Regorafenib—Leukopenia—Doxorubicin—stomach cancer	8.08e-05	0.000853	CcSEcCtD
Regorafenib—Diarrhoea—Docetaxel—stomach cancer	8.07e-05	0.000853	CcSEcCtD
Regorafenib—Infection—Epirubicin—stomach cancer	7.91e-05	0.000835	CcSEcCtD
Regorafenib—Diarrhoea—Capecitabine—stomach cancer	7.82e-05	0.000826	CcSEcCtD
Regorafenib—Nervous system disorder—Epirubicin—stomach cancer	7.81e-05	0.000825	CcSEcCtD
Regorafenib—Thrombocytopenia—Epirubicin—stomach cancer	7.79e-05	0.000823	CcSEcCtD
Regorafenib—Hypertension—Doxorubicin—stomach cancer	7.79e-05	0.000823	CcSEcCtD
Regorafenib—Skin disorder—Epirubicin—stomach cancer	7.73e-05	0.000817	CcSEcCtD
Regorafenib—ABCB1—endocrine gland—stomach cancer	7.7e-05	0.000936	CbGeAlD
Regorafenib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	7.63e-05	0.000806	CcSEcCtD
Regorafenib—Dry mouth—Doxorubicin—stomach cancer	7.51e-05	0.000794	CcSEcCtD
Regorafenib—Vomiting—Docetaxel—stomach cancer	7.5e-05	0.000793	CcSEcCtD
Regorafenib—Rash—Docetaxel—stomach cancer	7.44e-05	0.000786	CcSEcCtD
Regorafenib—Dermatitis—Docetaxel—stomach cancer	7.43e-05	0.000785	CcSEcCtD
Regorafenib—Decreased appetite—Methotrexate—stomach cancer	7.39e-05	0.000781	CcSEcCtD
Regorafenib—Headache—Docetaxel—stomach cancer	7.39e-05	0.000781	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Methotrexate—stomach cancer	7.34e-05	0.000776	CcSEcCtD
Regorafenib—Fatigue—Methotrexate—stomach cancer	7.33e-05	0.000775	CcSEcCtD
Regorafenib—Infection—Doxorubicin—stomach cancer	7.32e-05	0.000773	CcSEcCtD
Regorafenib—Pain—Methotrexate—stomach cancer	7.27e-05	0.000768	CcSEcCtD
Regorafenib—Vomiting—Capecitabine—stomach cancer	7.26e-05	0.000767	CcSEcCtD
Regorafenib—Nervous system disorder—Doxorubicin—stomach cancer	7.22e-05	0.000763	CcSEcCtD
Regorafenib—Thrombocytopenia—Doxorubicin—stomach cancer	7.21e-05	0.000762	CcSEcCtD
Regorafenib—Rash—Capecitabine—stomach cancer	7.2e-05	0.000761	CcSEcCtD
Regorafenib—Dermatitis—Capecitabine—stomach cancer	7.2e-05	0.00076	CcSEcCtD
Regorafenib—Headache—Capecitabine—stomach cancer	7.16e-05	0.000756	CcSEcCtD
Regorafenib—Skin disorder—Doxorubicin—stomach cancer	7.15e-05	0.000756	CcSEcCtD
Regorafenib—Nausea—Docetaxel—stomach cancer	7.01e-05	0.000741	CcSEcCtD
Regorafenib—Gastrointestinal pain—Methotrexate—stomach cancer	6.96e-05	0.000735	CcSEcCtD
Regorafenib—ABCB1—liver—stomach cancer	6.94e-05	0.000844	CbGeAlD
Regorafenib—Decreased appetite—Epirubicin—stomach cancer	6.92e-05	0.000731	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Epirubicin—stomach cancer	6.87e-05	0.000726	CcSEcCtD
Regorafenib—Fatigue—Epirubicin—stomach cancer	6.86e-05	0.000725	CcSEcCtD
Regorafenib—Pain—Epirubicin—stomach cancer	6.81e-05	0.000719	CcSEcCtD
Regorafenib—Nausea—Capecitabine—stomach cancer	6.79e-05	0.000717	CcSEcCtD
Regorafenib—Abdominal pain—Methotrexate—stomach cancer	6.72e-05	0.00071	CcSEcCtD
Regorafenib—Body temperature increased—Methotrexate—stomach cancer	6.72e-05	0.00071	CcSEcCtD
Regorafenib—Gastrointestinal pain—Epirubicin—stomach cancer	6.51e-05	0.000688	CcSEcCtD
Regorafenib—Decreased appetite—Doxorubicin—stomach cancer	6.4e-05	0.000676	CcSEcCtD
Regorafenib—Gastrointestinal disorder—Doxorubicin—stomach cancer	6.36e-05	0.000672	CcSEcCtD
Regorafenib—Fatigue—Doxorubicin—stomach cancer	6.35e-05	0.000671	CcSEcCtD
Regorafenib—Pain—Doxorubicin—stomach cancer	6.3e-05	0.000665	CcSEcCtD
Regorafenib—Abdominal pain—Epirubicin—stomach cancer	6.29e-05	0.000665	CcSEcCtD
Regorafenib—Body temperature increased—Epirubicin—stomach cancer	6.29e-05	0.000665	CcSEcCtD
Regorafenib—Asthenia—Methotrexate—stomach cancer	6.1e-05	0.000645	CcSEcCtD
Regorafenib—Gastrointestinal pain—Doxorubicin—stomach cancer	6.02e-05	0.000636	CcSEcCtD
Regorafenib—Abdominal pain—Doxorubicin—stomach cancer	5.82e-05	0.000615	CcSEcCtD
Regorafenib—Body temperature increased—Doxorubicin—stomach cancer	5.82e-05	0.000615	CcSEcCtD
Regorafenib—Diarrhoea—Methotrexate—stomach cancer	5.82e-05	0.000615	CcSEcCtD
Regorafenib—Asthenia—Epirubicin—stomach cancer	5.71e-05	0.000603	CcSEcCtD
Regorafenib—Diarrhoea—Epirubicin—stomach cancer	5.45e-05	0.000575	CcSEcCtD
Regorafenib—Vomiting—Methotrexate—stomach cancer	5.41e-05	0.000571	CcSEcCtD
Regorafenib—Rash—Methotrexate—stomach cancer	5.36e-05	0.000567	CcSEcCtD
Regorafenib—Dermatitis—Methotrexate—stomach cancer	5.36e-05	0.000566	CcSEcCtD
Regorafenib—Headache—Methotrexate—stomach cancer	5.33e-05	0.000563	CcSEcCtD
Regorafenib—ABCB1—lymph node—stomach cancer	5.32e-05	0.000647	CbGeAlD
Regorafenib—Asthenia—Doxorubicin—stomach cancer	5.28e-05	0.000558	CcSEcCtD
Regorafenib—Vomiting—Epirubicin—stomach cancer	5.06e-05	0.000535	CcSEcCtD
Regorafenib—Nausea—Methotrexate—stomach cancer	5.05e-05	0.000534	CcSEcCtD
Regorafenib—Diarrhoea—Doxorubicin—stomach cancer	5.04e-05	0.000532	CcSEcCtD
Regorafenib—Rash—Epirubicin—stomach cancer	5.02e-05	0.00053	CcSEcCtD
Regorafenib—Dermatitis—Epirubicin—stomach cancer	5.01e-05	0.00053	CcSEcCtD
Regorafenib—Headache—Epirubicin—stomach cancer	4.99e-05	0.000527	CcSEcCtD
Regorafenib—Nausea—Epirubicin—stomach cancer	4.73e-05	0.0005	CcSEcCtD
Regorafenib—Vomiting—Doxorubicin—stomach cancer	4.68e-05	0.000495	CcSEcCtD
Regorafenib—Rash—Doxorubicin—stomach cancer	4.64e-05	0.000491	CcSEcCtD
Regorafenib—Dermatitis—Doxorubicin—stomach cancer	4.64e-05	0.00049	CcSEcCtD
Regorafenib—Headache—Doxorubicin—stomach cancer	4.61e-05	0.000487	CcSEcCtD
Regorafenib—Nausea—Doxorubicin—stomach cancer	4.37e-05	0.000462	CcSEcCtD
Regorafenib—FGFR1—Signaling Pathways—CCND1—stomach cancer	1.31e-06	7.89e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—STAT3—stomach cancer	1.31e-06	7.89e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—JUN—stomach cancer	1.31e-06	7.88e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CCND1—stomach cancer	1.31e-06	7.87e-06	CbGpPWpGaD
Regorafenib—BRAF—Disease—IL6—stomach cancer	1.31e-06	7.87e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—JUN—stomach cancer	1.3e-06	7.86e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MAPK8—stomach cancer	1.3e-06	7.85e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GSTP1—stomach cancer	1.3e-06	7.8e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—STAT3—stomach cancer	1.29e-06	7.79e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ALOX5—stomach cancer	1.29e-06	7.78e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PPP2R1A—stomach cancer	1.29e-06	7.76e-06	CbGpPWpGaD
Regorafenib—KIT—Immune System—IL6—stomach cancer	1.29e-06	7.76e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—CAV1—stomach cancer	1.28e-06	7.73e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—RHOA—stomach cancer	1.28e-06	7.73e-06	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—PIK3CA—stomach cancer	1.28e-06	7.73e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—APOA1—stomach cancer	1.28e-06	7.72e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—HMOX1—stomach cancer	1.28e-06	7.69e-06	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—HRAS—stomach cancer	1.28e-06	7.69e-06	CbGpPWpGaD
Regorafenib—FGFR1—Disease—PIK3CA—stomach cancer	1.27e-06	7.67e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—MAPK1—stomach cancer	1.27e-06	7.67e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—EGFR—stomach cancer	1.27e-06	7.67e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—HRAS—stomach cancer	1.27e-06	7.67e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MMP9—stomach cancer	1.27e-06	7.66e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—DPYD—stomach cancer	1.27e-06	7.66e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—PIK3CA—stomach cancer	1.27e-06	7.65e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NOS3—stomach cancer	1.27e-06	7.65e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MMP9—stomach cancer	1.27e-06	7.64e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CDKN1A—stomach cancer	1.27e-06	7.63e-06	CbGpPWpGaD
Regorafenib—FGFR2—Disease—HRAS—stomach cancer	1.26e-06	7.62e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GSTP1—stomach cancer	1.26e-06	7.62e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CDKN1A—stomach cancer	1.26e-06	7.62e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CXCL8—stomach cancer	1.26e-06	7.61e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MAPK3—stomach cancer	1.26e-06	7.61e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ERCC2—stomach cancer	1.25e-06	7.55e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MAPK3—stomach cancer	1.25e-06	7.53e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—HMOX1—stomach cancer	1.25e-06	7.51e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—KRAS—stomach cancer	1.25e-06	7.51e-06	CbGpPWpGaD
Regorafenib—KIT—Disease—HRAS—stomach cancer	1.24e-06	7.48e-06	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—TP53—stomach cancer	1.24e-06	7.48e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—PIK3CA—stomach cancer	1.24e-06	7.47e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MAPK8—stomach cancer	1.24e-06	7.45e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—MAPK3—stomach cancer	1.24e-06	7.44e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CDKN1B—stomach cancer	1.23e-06	7.43e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MAPK8—stomach cancer	1.23e-06	7.43e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MYC—stomach cancer	1.23e-06	7.4e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—VEGFA—stomach cancer	1.23e-06	7.38e-06	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—IL6—stomach cancer	1.22e-06	7.36e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—IL6—stomach cancer	1.22e-06	7.34e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MYC—stomach cancer	1.22e-06	7.33e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—STAT3—stomach cancer	1.21e-06	7.31e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—PIK3CA—stomach cancer	1.21e-06	7.3e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PTGS2—stomach cancer	1.21e-06	7.3e-06	CbGpPWpGaD
Regorafenib—FGFR2—Disease—IL6—stomach cancer	1.21e-06	7.29e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—PIK3CA—stomach cancer	1.21e-06	7.29e-06	CbGpPWpGaD
Regorafenib—ABL1—Immune System—PIK3CA—stomach cancer	1.21e-06	7.28e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—TYMS—stomach cancer	1.2e-06	7.25e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PPP2R1A—stomach cancer	1.2e-06	7.25e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—VEGFA—stomach cancer	1.2e-06	7.25e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—KRAS—stomach cancer	1.2e-06	7.25e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—MYC—stomach cancer	1.2e-06	7.24e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—MAPK1—stomach cancer	1.2e-06	7.24e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—EGFR—stomach cancer	1.2e-06	7.24e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—STAT3—stomach cancer	1.19e-06	7.18e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—GSTM1—stomach cancer	1.19e-06	7.17e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—MAPK1—stomach cancer	1.19e-06	7.17e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—EGFR—stomach cancer	1.19e-06	7.17e-06	CbGpPWpGaD
Regorafenib—KIT—Disease—IL6—stomach cancer	1.19e-06	7.16e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—ERBB2—stomach cancer	1.19e-06	7.15e-06	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—HRAS—stomach cancer	1.19e-06	7.15e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GSTP1—stomach cancer	1.18e-06	7.11e-06	CbGpPWpGaD
Regorafenib—FGFR1—Disease—HRAS—stomach cancer	1.18e-06	7.1e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—MTHFR—stomach cancer	1.18e-06	7.1e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CCND1—stomach cancer	1.18e-06	7.09e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—MAPK1—stomach cancer	1.18e-06	7.08e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—EGFR—stomach cancer	1.18e-06	7.08e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—HRAS—stomach cancer	1.18e-06	7.08e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—TYMS—stomach cancer	1.18e-06	7.08e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—JUN—stomach cancer	1.17e-06	7.08e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TP53—stomach cancer	1.17e-06	7.06e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—HMOX1—stomach cancer	1.16e-06	7.02e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—GSTM1—stomach cancer	1.16e-06	7e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MAPK3—stomach cancer	1.16e-06	6.98e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—HRAS—stomach cancer	1.15e-06	6.91e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—PIK3CA—stomach cancer	1.14e-06	6.9e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MMP9—stomach cancer	1.14e-06	6.89e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—VEGFA—stomach cancer	1.14e-06	6.88e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—VEGFA—stomach cancer	1.14e-06	6.86e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CDKN1A—stomach cancer	1.14e-06	6.86e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MAPK3—stomach cancer	1.14e-06	6.86e-06	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—IL6—stomach cancer	1.14e-06	6.84e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—KRAS—stomach cancer	1.13e-06	6.84e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—STAT3—stomach cancer	1.13e-06	6.81e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PPARG—stomach cancer	1.13e-06	6.8e-06	CbGpPWpGaD
Regorafenib—FGFR1—Disease—IL6—stomach cancer	1.13e-06	6.8e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—STAT3—stomach cancer	1.13e-06	6.8e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MYC—stomach cancer	1.13e-06	6.79e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CXCL8—stomach cancer	1.13e-06	6.78e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—IL6—stomach cancer	1.13e-06	6.78e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—KRAS—stomach cancer	1.12e-06	6.77e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GSTT1—stomach cancer	1.12e-06	6.77e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—HRAS—stomach cancer	1.12e-06	6.76e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ERCC2—stomach cancer	1.12e-06	6.74e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—HRAS—stomach cancer	1.12e-06	6.74e-06	CbGpPWpGaD
Regorafenib—ABL1—Immune System—HRAS—stomach cancer	1.12e-06	6.73e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MAPK8—stomach cancer	1.11e-06	6.7e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CYP2A6—stomach cancer	1.11e-06	6.69e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—KRAS—stomach cancer	1.11e-06	6.69e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MYC—stomach cancer	1.11e-06	6.67e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—PIK3CA—stomach cancer	1.11e-06	6.66e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—MAPK1—stomach cancer	1.1e-06	6.64e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—EGFR—stomach cancer	1.1e-06	6.64e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CDKN1B—stomach cancer	1.1e-06	6.63e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—TYMS—stomach cancer	1.1e-06	6.61e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—IL6—stomach cancer	1.1e-06	6.61e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ERCC2—stomach cancer	1.09e-06	6.58e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CAV1—stomach cancer	1.09e-06	6.55e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—GSTM1—stomach cancer	1.09e-06	6.54e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—APOA1—stomach cancer	1.08e-06	6.53e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—MAPK1—stomach cancer	1.08e-06	6.53e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—EGFR—stomach cancer	1.08e-06	6.52e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—AKR1C3—stomach cancer	1.08e-06	6.51e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MAPK3—stomach cancer	1.08e-06	6.51e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MAPK3—stomach cancer	1.08e-06	6.49e-06	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—IL6—stomach cancer	1.07e-06	6.47e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—IL6—stomach cancer	1.07e-06	6.45e-06	CbGpPWpGaD
Regorafenib—ABL1—Immune System—IL6—stomach cancer	1.07e-06	6.45e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—HRAS—stomach cancer	1.06e-06	6.38e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ENO1—stomach cancer	1.05e-06	6.34e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—MTHFR—stomach cancer	1.05e-06	6.34e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MYC—stomach cancer	1.05e-06	6.33e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CCND1—stomach cancer	1.05e-06	6.32e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MYC—stomach cancer	1.05e-06	6.31e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—JUN—stomach cancer	1.05e-06	6.31e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—PIK3CA—stomach cancer	1.04e-06	6.28e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—KRAS—stomach cancer	1.04e-06	6.28e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	1.04e-06	6.26e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—PIK3CA—stomach cancer	1.03e-06	6.22e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—MAPK1—stomach cancer	1.03e-06	6.19e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—EGFR—stomach cancer	1.03e-06	6.19e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—MTHFR—stomach cancer	1.03e-06	6.18e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—VEGFA—stomach cancer	1.03e-06	6.18e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MAPK1—stomach cancer	1.03e-06	6.18e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—EGFR—stomach cancer	1.03e-06	6.18e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—KRAS—stomach cancer	1.02e-06	6.16e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—HRAS—stomach cancer	1.02e-06	6.16e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ERCC2—stomach cancer	1.02e-06	6.15e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—PIK3CA—stomach cancer	1.02e-06	6.15e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MMP9—stomach cancer	1.02e-06	6.14e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—STAT3—stomach cancer	1.02e-06	6.12e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CDKN1A—stomach cancer	1.02e-06	6.11e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—ALB—stomach cancer	1.01e-06	6.11e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—IL6—stomach cancer	1.01e-06	6.11e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TP53—stomach cancer	1.01e-06	6.08e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TP53—stomach cancer	9.99e-07	6.02e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MAPK8—stomach cancer	9.91e-07	5.97e-06	CbGpPWpGaD
Regorafenib—RAF1—Immune System—IL6—stomach cancer	9.79e-07	5.89e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—KRAS—stomach cancer	9.71e-07	5.85e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—NOS3—stomach cancer	9.71e-07	5.85e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MAPK3—stomach cancer	9.71e-07	5.85e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CAV1—stomach cancer	9.7e-07	5.84e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—KRAS—stomach cancer	9.68e-07	5.83e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—APOA1—stomach cancer	9.68e-07	5.83e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—HRAS—stomach cancer	9.64e-07	5.81e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—MTHFR—stomach cancer	9.59e-07	5.78e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—PIK3CA—stomach cancer	9.57e-07	5.77e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PPARG—stomach cancer	9.56e-07	5.76e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—HRAS—stomach cancer	9.55e-07	5.76e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CAV1—stomach cancer	9.47e-07	5.7e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—APOA1—stomach cancer	9.45e-07	5.69e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MYC—stomach cancer	9.44e-07	5.69e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—HRAS—stomach cancer	9.44e-07	5.69e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—PIK3CA—stomach cancer	9.4e-07	5.66e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CD44—stomach cancer	9.34e-07	5.63e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	9.27e-07	5.58e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TP53—stomach cancer	9.26e-07	5.58e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MAPK1—stomach cancer	9.24e-07	5.56e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—EGFR—stomach cancer	9.24e-07	5.56e-06	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—IL6—stomach cancer	9.23e-07	5.56e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—VEGFA—stomach cancer	9.15e-07	5.51e-06	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—IL6—stomach cancer	9.14e-07	5.51e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TP53—stomach cancer	9.09e-07	5.48e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—STAT3—stomach cancer	9.06e-07	5.46e-06	CbGpPWpGaD
Regorafenib—RAF1—Disease—IL6—stomach cancer	9.03e-07	5.44e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—PIK3CA—stomach cancer	8.92e-07	5.37e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—PIK3CA—stomach cancer	8.9e-07	5.36e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PTGS2—stomach cancer	8.88e-07	5.35e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—HRAS—stomach cancer	8.85e-07	5.33e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CAV1—stomach cancer	8.85e-07	5.33e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—APOA1—stomach cancer	8.83e-07	5.32e-06	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PIK3CA—stomach cancer	8.78e-07	5.29e-06	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PIK3CA—stomach cancer	8.78e-07	5.29e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—KRAS—stomach cancer	8.73e-07	5.26e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—HRAS—stomach cancer	8.7e-07	5.24e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MAPK3—stomach cancer	8.65e-07	5.21e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TP53—stomach cancer	8.63e-07	5.2e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TP53—stomach cancer	8.61e-07	5.19e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—ALB—stomach cancer	8.59e-07	5.18e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PPARG—stomach cancer	8.53e-07	5.14e-06	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—IL6—stomach cancer	8.47e-07	5.11e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	8.45e-07	5.09e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MYC—stomach cancer	8.42e-07	5.07e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PPARG—stomach cancer	8.33e-07	5.02e-06	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—IL6—stomach cancer	8.32e-07	5.01e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—HRAS—stomach cancer	8.25e-07	4.97e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MAPK1—stomach cancer	8.23e-07	4.96e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—EGFR—stomach cancer	8.23e-07	4.96e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—HRAS—stomach cancer	8.23e-07	4.96e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—NOS3—stomach cancer	8.22e-07	4.95e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—PIK3CA—stomach cancer	8.02e-07	4.83e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PPP2R1A—stomach cancer	7.94e-07	4.78e-06	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—IL6—stomach cancer	7.9e-07	4.76e-06	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—IL6—stomach cancer	7.88e-07	4.75e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GSTP1—stomach cancer	7.79e-07	4.69e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PPARG—stomach cancer	7.78e-07	4.69e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—KRAS—stomach cancer	7.78e-07	4.68e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TP53—stomach cancer	7.75e-07	4.67e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—HMOX1—stomach cancer	7.68e-07	4.63e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—ALB—stomach cancer	7.67e-07	4.62e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PTGS2—stomach cancer	7.52e-07	4.53e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—ALB—stomach cancer	7.49e-07	4.51e-06	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PIK3CA—stomach cancer	7.45e-07	4.49e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—HRAS—stomach cancer	7.42e-07	4.47e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—NOS3—stomach cancer	7.34e-07	4.42e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—TYMS—stomach cancer	7.24e-07	4.36e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—NOS3—stomach cancer	7.16e-07	4.31e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—GSTM1—stomach cancer	7.16e-07	4.31e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PIK3CA—stomach cancer	7.14e-07	4.3e-06	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—IL6—stomach cancer	7.1e-07	4.28e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—ALB—stomach cancer	6.99e-07	4.21e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TP53—stomach cancer	6.91e-07	4.16e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ERCC2—stomach cancer	6.73e-07	4.05e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PTGS2—stomach cancer	6.71e-07	4.04e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—NOS3—stomach cancer	6.69e-07	4.03e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—HRAS—stomach cancer	6.61e-07	3.98e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PTGS2—stomach cancer	6.55e-07	3.95e-06	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—IL6—stomach cancer	6.33e-07	3.81e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—MTHFR—stomach cancer	6.33e-07	3.81e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PTGS2—stomach cancer	6.12e-07	3.69e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CAV1—stomach cancer	5.83e-07	3.51e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—APOA1—stomach cancer	5.82e-07	3.51e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CA—stomach cancer	5.46e-07	3.29e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PPARG—stomach cancer	5.13e-07	3.09e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CA—stomach cancer	4.63e-07	2.79e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ALB—stomach cancer	4.61e-07	2.78e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NOS3—stomach cancer	4.41e-07	2.66e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CA—stomach cancer	4.13e-07	2.49e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PTGS2—stomach cancer	4.04e-07	2.43e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CA—stomach cancer	4.03e-07	2.43e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CA—stomach cancer	3.76e-07	2.27e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CA—stomach cancer	2.48e-07	1.5e-06	CbGpPWpGaD
